Skip to content

Evaluation of vitamin D,E combination therapy on women with primary Dysmenorrhea

Evaluation of Vitamin D,E Combination Therapy on women with Primary Dysmenorrhea in Imam Hossein Hospital

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220720055506N1
Enrollment
126
Registered
2023-02-01
Start date
2021-10-09
Completion date
Unknown
Last updated
2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary dysmenorrhea. Primary dysmenorrhea

Interventions

Intervention 1: Intervention group:Women aged 15 to 35 with a diagnosis of primary dysmenorrhea, taking into account the inclusion criteria and obtaining informed consent, vitamin E (400U) tablets tak

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
15 Years to 35 Years

Inclusion criteria

Inclusion criteria: -All patients with regular menses (with an interval of 21 to 35 days between the two menses, lasting for 3 to 7 days) and experiencing at least four painful cycles within six months beginning the day before the menses or at the very day of menses. -Inclination to participate in the study -Vitamin D level less than 30 ng/ml

Exclusion criteria

Exclusion criteria: Patients with pelvic disorders (endometriosis, myoma etc.) Systemic disorders/acute infectious disease and in general secondary dysmenorrhea Patients using calcium, vitamin D and E supplements regularly Patients with urinary tract lithiasis or a history of the disease Vitamin D level above 30 ng/ml

Design outcomes

Primary

MeasureTime frame
Dysmenorrhoea pain severity score in the NUMERICAL PAIN RATING SCALE scoring system. Timepoint: Before starting treatment, 2 months and 4 months after starting treatment. Method of measurement: NUMERICAL PAIN RATING SCALE scoring system.;Premenstrual symptoms severity level in the 21-item PMS standard questionnaire. Timepoint: Before starting treatment, 2 months and 4 months after starting treatment. Method of measurement: Standard Premenstrual Symptoms Questionnaire of 21 items.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFateme Abdollahi Aliabadi

Shahid Beheshti University of Medical Sciences

fatimaa.abdollahi@gmail.com+98 21 7343 2320

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026